TYSONS CORNER, Va. (PRWEB) September 20, 2021 — Clinical trials of new drugs and treatments have a high failure rate. Better planning and technology-aided communication, says Dr. Harsha Rajasimha of Jeeva Informatics, can significantly reduce the number of participants who drop out, thus improving the chances of success—for the trials and the therapeutic product itself.
In recognition of Rare Disease Day 2021, Jeeva Informatics (Jeeva) brought together a panel of experts to discuss the importance of transforming the clinical trial process for rare diseases. The panel included Annie Kennedy, Chief of Policy and Advocacy, EveryLife Foundation for Rare Diseases; Thomas Lester, Former Executive Director, Audentes Therapeutics; Scott Schliebner, Senior Vice President, Scientific Affairs & Therapeutic Expertise, PRA Health Sciences; and Dr. Eric Sid, Program Director, National Center for Advancing Translational Science, Office of Rare Disease Research, (NCATS)/NIH.
This Startup is on a Mission to Decentralize Cell and Gene Therapy Clinical Trials For the cell and gene therapy revolution to be fully realized, physicians, research scientists, biomanufacturing experts, [….]
In Conversation: Dr. Harsha K. Rajasimha, IndoUSrare BioBuzz recently sat down for a conversation with Dr. Harsha K. Rajasimha, a leading rare disease advocate, the founder of the non-profit, IndoUSrare, [….]
